View Older Stories
-
Bristol Myers Squibb gains EU approval for Opdivo combination in lymphoma
-
Bristol Myers Squibb drug reduces multiple myeloma progression risk by 52%
-
UBS Reiterates Buy Rating on Bristol-Myers Squibb Co. (BMY)
-
Bristol Myers Squibb to present 60+ oncology studies at ASCO 2026
-
Bristol-Myers Squibb (BMY) brings Anthropic’s Claude to 30,000 of its staff - WSJ
-
Bernstein SocGen on Bristol-Myers Squibb Co. (BMY): 'Hengrui deal highlights acceleration possibilities in China'
-
Pacira BioSciences urges stockholders to support board nominees
-
BMO Capital Reiterates Market Perform Rating on Bristol-Myers Squibb Co. (BMY)
-
Bristol Myers Squibb gets EU approval for Sotyktu to treat psoriatic arthritis
-
BMO Capital Reiterates Market Perform Rating on Bristol-Myers Squibb Co. (BMY)
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $60 at BMO Capital
-
BofA: Bristol update may boost Cytokinetics shares
-
Bristol-Myers Squibb (BMY) Tops Q1 EPS by 16c; reaffirms guidance
-
Bristol Myers Squibb and Pfizer partner with Mark Cuban's Cost Plus Drugs
-
Atrium Therapeutics receives $15 million milestone from Bristol Myers Squibb
-
Raymond James Preview Bristol-Myers Squibb Co. (BMY) Earnings: 'Our updated diluted non-GAAP EPS is $1.49 for 1Q26 '
-
Bristol-Myers Squibb Co. (BMY) PT Lowered to $67 at BofA Securities
-
Bristol-Myers Squibb (BMY) Reiterated at Neutral by Cantor Fitzgerald on Eliquis Outlook
-
Guggenheim Reiterates Buy Rating on Bristol-Myers Squibb Co. (BMY)
-
Bristol Myers Squibb Evolves and Expands Standing in the Gaap To Advance More Equitable Care in Multiple Myeloma As Program Marks Ten Years
-
Bristol Myers Squibb expands multiple myeloma care program after decade
-
Bristol Myers Squibb study shows stable symptom transition to COBENFY
-
A New Era in Schizophrenia Care: National Council for Mental Wellbeing and Bristol Myers Squibb Collaborate to Advance Evidence-Based Care Models
-
insitro expands Bristol Myers Squibb partnership with two new ALS targets
-
Bristol Myers Squibb wins FDA and EU approvals for Opdivo in Hodgkin lymphoma
-
RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $70 at Jefferies: SUCCESSOR-2 interim validates CELMoD strategy
-
Raymond James looks for further durability in BMY's (BMY) MountainTAP-30 trial
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $70 at UBS Ahead of Major Catalyst
-
Bristol-Myers Squibb (BMY) Declares $0.63 Quarterly Dividend; 4% Yield
-
Stifel Earlier Defended Tango Therapeutics Inc. (TNGX) Amid 12pct Decline
-
Iza-bren meets dual endpoints in phase III breast cancer trial
-
RBC Capital Starts Bristol-Myers Squibb Co. (BMY) at Sector Perform
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $75 at Piper Sandler
-
Barclays Starts Bristol-Myers Squibb Co. (BMY) at Overweight
-
FDA accepts Bristol Myers Squibb drug application for multiple myeloma
-
Bristol-Myers Squibb receives orphan drug designation for lymphoma treatment
-
Bernstein Weighs In on Bristol-Myers Squibb (BMY) Ahead of H2 Critical Clinical Readouts
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $72 at Guggenheim
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $60 at Wells Fargo
-
Truist: 'We remain incrementally positive on BMY'
-
Bristol-Myers Squibb (BMY) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY26 Guidance
-
Stocks expected to have increasing option volume: BMY KKR CMI CI CBOE CARR CAH EL HSY TPR RL PTON AMZN MSTR BIIB ALGT MOD M KLIC HP
-
Bristol Myers Squibb partners with Kasey Keller on lymphoma awareness
-
Bristol-Myers Squibb (BMY) call put ratio 1.6 calls to 1 put into quarter results
-
Bristol Myers Squibb launches educational campaign on cardiovascular care
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $66 at Piper Sandler
-
Bristol Myers Squibb partners with Microsoft on lung cancer AI detection
-
Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer
-
Bristol Myers Squibb partners with Microsoft on AI lung cancer detection

